<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927781</url>
  </required_header>
  <id_info>
    <org_study_id>2013680</org_study_id>
    <nct_id>NCT03927781</nct_id>
  </id_info>
  <brief_title>Perioperative Pregabalin in Ureteroscopy: a Pilot</brief_title>
  <official_title>Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a pilot clinical trial on the use of perioperative pregabalin in&#xD;
      order to decrease ureteral stent related symptoms and decrease opioid usage after&#xD;
      ureteroscopy with stent placement. Patients undergoing ureteroscopy with stent placement will&#xD;
      receive a single dose of 300 mg pregabalin PO in the preoperative area. This work will assess&#xD;
      safety and feasibility of studying this regimen at our institution, with the aim of&#xD;
      performing a randomized, placebo-controlled, double-blinded study in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">October 17, 2020</completion_date>
  <primary_completion_date type="Actual">October 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All participants will receive 300mg PO pregabalin one hour before procedure start</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>There will be no blinding for this pilot</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Adverse Events Related to Study Drug</measure>
    <time_frame>Day of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Were Administered the Study Drug Correctly</measure>
    <time_frame>Day of surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Respondent Reported Usability of Instruments</measure>
    <time_frame>30 days post-op</time_frame>
    <description>Number of patients able to complete 30 day post op questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Post-op Stent Related Symptoms</measure>
    <time_frame>Post-op day 3</time_frame>
    <description>Ureteral Stent Related Symptom Questionnaire (USSQ) score, sum of urinary index score, pain index score, and general health index score. Minimum is 24. Maximum is 162. Higher scores indicate a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early Post-op Opioid Needs</measure>
    <time_frame>First 30 post-operative days</time_frame>
    <description>Number of patients with a verified prescription for narcotic medication within the first 30 post-operative days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid Use</measure>
    <time_frame>Up to 1 year post-op</time_frame>
    <description>Number of patients stating that they had used opioids on any survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Opioid Use</measure>
    <time_frame>Up to 1 year post-op</time_frame>
    <description>Total amount of opioid used for any indication at several time points, in oral morphine equivalents. This is the sum for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned Healthcare Contacts</measure>
    <time_frame>First 30 post-operative days</time_frame>
    <description>Number of unplanned contacts between the patient and the healthcare system. This is the total for all patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>First 30 post-operative days</time_frame>
    <description>Score on standardized evaluation of patient satisfaction at 7-days post-op. This was on a scale from 1) very dissatisfied to 5) very satisfied. Higher scores are better.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Nephrolithiasis</condition>
  <condition>Urolithiasis</condition>
  <condition>Perioperative/Postoperative Complications</condition>
  <condition>Pain, Postoperative</condition>
  <condition>Pain, Acute</condition>
  <condition>Anesthesia</condition>
  <condition>Urologic Diseases</condition>
  <condition>Anesthesia Morbidity</condition>
  <arm_group>
    <arm_group_label>Pregabalin 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg pregabalin, PO, once, 1 hr before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin 300mg</intervention_name>
    <description>One 300mg capsule will be administered PO 1 hour before surgery</description>
    <arm_group_label>Pregabalin 300mg</arm_group_label>
    <other_name>Lyrica</other_name>
    <other_name>Gabapentinoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subject Population Undergoing elective ureteroscopy with stent placement by Dr. Murray at&#xD;
        University of Missouri Hospital and affiliated facilities&#xD;
&#xD;
        Subject Inclusion&#xD;
&#xD;
        Age &gt;= 18 years&#xD;
&#xD;
        Subject Exclusion&#xD;
&#xD;
          -  Renal insufficiency (eGFR &lt; 30 mL/minute/1.73 m2)&#xD;
&#xD;
          -  Chronic indwelling ureteral stent&#xD;
&#xD;
          -  Chronic opioid use&#xD;
&#xD;
          -  History of opioid abuse&#xD;
&#xD;
          -  Chronic gabapentinoid use&#xD;
&#xD;
          -  Plan for inpatient hospitalization&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability of the patient to consent for themselves in English&#xD;
&#xD;
          -  Allergy to gabapentinoid&#xD;
&#xD;
          -  Liver failure or hepatic dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie Murray, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Missouri-Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <results_first_submitted>February 27, 2021</results_first_submitted>
  <results_first_submitted_qc>April 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Katie Murray</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Pregabalin</keyword>
  <keyword>Perioperative medicine</keyword>
  <keyword>Opioid sparing</keyword>
  <keyword>Urolithiasis</keyword>
  <keyword>Ureteroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
    <mesh_term>Urinary Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03927781/Prot_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03927781/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pregabalin 300mg</title>
          <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pregabalin 300mg</title>
          <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.2" lower_limit="20" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Adverse Events Related to Study Drug</title>
        <time_frame>Day of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Adverse Events Related to Study Drug</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Administered the Study Drug Correctly</title>
        <time_frame>Day of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Administered the Study Drug Correctly</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Respondent Reported Usability of Instruments</title>
        <description>Number of patients able to complete 30 day post op questionnaire</description>
        <time_frame>30 days post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Respondent Reported Usability of Instruments</title>
          <description>Number of patients able to complete 30 day post op questionnaire</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Post-op Stent Related Symptoms</title>
        <description>Ureteral Stent Related Symptom Questionnaire (USSQ) score, sum of urinary index score, pain index score, and general health index score. Minimum is 24. Maximum is 162. Higher scores indicate a worse outcome.</description>
        <time_frame>Post-op day 3</time_frame>
        <population>Those who completed the questionnaire</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Early Post-op Stent Related Symptoms</title>
          <description>Ureteral Stent Related Symptom Questionnaire (USSQ) score, sum of urinary index score, pain index score, and general health index score. Minimum is 24. Maximum is 162. Higher scores indicate a worse outcome.</description>
          <population>Those who completed the questionnaire</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="61" upper_limit="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Early Post-op Opioid Needs</title>
        <description>Number of patients with a verified prescription for narcotic medication within the first 30 post-operative days.</description>
        <time_frame>First 30 post-operative days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Early Post-op Opioid Needs</title>
          <description>Number of patients with a verified prescription for narcotic medication within the first 30 post-operative days.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Use</title>
        <description>Number of patients stating that they had used opioids on any survey.</description>
        <time_frame>Up to 1 year post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Use</title>
          <description>Number of patients stating that they had used opioids on any survey.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Opioid Use</title>
        <description>Total amount of opioid used for any indication at several time points, in oral morphine equivalents. This is the sum for all patients.</description>
        <time_frame>Up to 1 year post-op</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Opioid Use</title>
          <description>Total amount of opioid used for any indication at several time points, in oral morphine equivalents. This is the sum for all patients.</description>
          <units>oral morphine equivalents</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Unplanned Healthcare Contacts</title>
        <description>Number of unplanned contacts between the patient and the healthcare system. This is the total for all patients.</description>
        <time_frame>First 30 post-operative days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Unplanned Healthcare Contacts</title>
          <description>Number of unplanned contacts between the patient and the healthcare system. This is the total for all patients.</description>
          <units>visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Score on standardized evaluation of patient satisfaction at 7-days post-op. This was on a scale from 1) very dissatisfied to 5) very satisfied. Higher scores are better.</description>
        <time_frame>First 30 post-operative days</time_frame>
        <population>Respondents to the survey</population>
        <group_list>
          <group group_id="O1">
            <title>Pregabalin 300mg</title>
            <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Score on standardized evaluation of patient satisfaction at 7-days post-op. This was on a scale from 1) very dissatisfied to 5) very satisfied. Higher scores are better.</description>
          <population>Respondents to the survey</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Events were systematically characterized on the day of surgery. Adverse events were otherwise by report up to 30 days after the patient's procedure.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pregabalin 300mg</title>
          <description>300mg pregabalin, PO, once, 1 hr before surgery&#xD;
Pregabalin 300mg: One 300mg capsule will be administered PO 1 hour before surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Katie Murray</name_or_title>
      <organization>University of Missouri</organization>
      <phone>573-884-8768</phone>
      <email>murraykat@health.missouri.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

